FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W9256820> ?p ?o ?g. }

• W9256820 abstract "Abstract Introduction Malignant cells require amino acids for a wide range of core functions. Amino acid deprivation using enzymatic degradation has been used to induce remission in acute lymphoblastic leukemia for decades. Amino acid deprivation may also benefit patients with acute myeloid leukemia (AML). We have previously shown that AML cells lack of argininosuccinate synthetase 1(ASS1), a key enzyme in the pathway that produces arginine (1). Here we tested the effect of an arginine depleting agent, pegylated arginine deiminase (ADI-PEG 20) on primary AML cells in a xenograft model of AML. Methods NOD/SCID/interleukin 2 gamma chain null (NSG) mice were transplanted with 6 primary AML samples. 12 weeks after transplantation of AML mice received either ADI-PEG 20, cytarabine, ADI-PEG 20 plus cytarabine or vehicle. ADI was administered weekly for 4 doses and cytarabine was given for 10 consecutive days (0.2mg per day, roughly equivalent to 40mg in humans). Five weeks after treatment started, mice were killed and the percentage of AML in the bone marrow was determined by flow cytometry. Blood was collected to quantify plasma arginine using liquid chromatography-mass spectrometry/mass spectrometry. Results Plasma arginine levels were depressed following ADI-PEG 20 administration confirming that arginine depletion was achieved in vivo. In all six experiments the combination of ADI-PEG 20 and cytarabine induced a significant reduction in levels of AML compared to control (Figure 1). Critically the combination of ADI-PEG 20 and cytarabine was significantly better than cytarabine alone in three of six experiments. Conclusion Our experiments show that arginine deprivation by ADI-PEG 20 can decrease the leukemic burden in mice transplanted with primary AML cells. The combination of ADI with cytarabine had a greater effect than cytarabine alone in half the experiments. These results provide the rationale to test ADI-PEG 20 with cytarabine in clinical trials. 1. Peter W. Szlosarek, Fiona Luong, Andrew Clear, David Taussig, Simon Joel, Maria Calaminici, Silvana Debernardi, Jude Fitzgibbon, John S. Bomalaski, Arthur E. Frankel, and Dominique Bonnet. Pegylated arginine deiminase (ADI-PEG 20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia. Cancer Research: April 15, 2011. AACR 102nd Annual Meeting 2011, (AACR Abstract # 467) F. M-M and L. A-M contributed equally D.B., P.W.S. and D.C.T contributed equally Disclosures: Bomalaski: Polaris Group: Employment, Equity Ownership. Szlosarek:Polaris Group: Research Funding." @default.
• W9256820 created "2016-06-24" @default.
• W9256820 creator A5007808102 @default.
• W9256820 creator A5016016794 @default.
• W9256820 creator A5022032908 @default.
• W9256820 creator A5022945467 @default.
• W9256820 creator A5023224181 @default.
• W9256820 creator A5026718910 @default.
• W9256820 creator A5039475933 @default.
• W9256820 creator A5046963415 @default.
• W9256820 creator A5064287027 @default.
• W9256820 creator A5066521737 @default.
• W9256820 creator A5067154165 @default.
• W9256820 creator A5082370164 @default.
• W9256820 date "2013-11-15" @default.
• W9256820 modified "2023-09-28" @default.
• W9256820 title "Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo" @default.
• W9256820 doi "https://doi.org/10.1182/blood.v122.21.1458.1458" @default.
• W9256820 hasPublicationYear "2013" @default.
• W9256820 type Work @default.
• W9256820 sameAs 9256820 @default.
• W9256820 citedByCount "1" @default.
• W9256820 countsByYear W92568202016 @default.
• W9256820 crossrefType "journal-article" @default.
• W9256820 hasAuthorship W9256820A5007808102 @default.
• W9256820 hasAuthorship W9256820A5016016794 @default.
• W9256820 hasAuthorship W9256820A5022032908 @default.
• W9256820 hasAuthorship W9256820A5022945467 @default.
• W9256820 hasAuthorship W9256820A5023224181 @default.
• W9256820 hasAuthorship W9256820A5026718910 @default.
• W9256820 hasAuthorship W9256820A5039475933 @default.
• W9256820 hasAuthorship W9256820A5046963415 @default.
• W9256820 hasAuthorship W9256820A5064287027 @default.
• W9256820 hasAuthorship W9256820A5066521737 @default.
• W9256820 hasAuthorship W9256820A5067154165 @default.
• W9256820 hasAuthorship W9256820A5082370164 @default.
• W9256820 hasConcept C126322002 @default.
• W9256820 hasConcept C150903083 @default.
• W9256820 hasConcept C185592680 @default.
• W9256820 hasConcept C188610204 @default.
• W9256820 hasConcept C203014093 @default.
• W9256820 hasConcept C207001950 @default.
• W9256820 hasConcept C2777186326 @default.
• W9256820 hasConcept C2777468819 @default.
• W9256820 hasConcept C2778041864 @default.
• W9256820 hasConcept C2778729363 @default.
• W9256820 hasConcept C2779129087 @default.
• W9256820 hasConcept C2779282312 @default.
• W9256820 hasConcept C2780007613 @default.
• W9256820 hasConcept C2911091166 @default.
• W9256820 hasConcept C515207424 @default.
• W9256820 hasConcept C55493867 @default.
• W9256820 hasConcept C71924100 @default.
• W9256820 hasConcept C86803240 @default.
• W9256820 hasConcept C98274493 @default.
• W9256820 hasConceptScore W9256820C126322002 @default.
• W9256820 hasConceptScore W9256820C150903083 @default.
• W9256820 hasConceptScore W9256820C185592680 @default.
• W9256820 hasConceptScore W9256820C188610204 @default.
• W9256820 hasConceptScore W9256820C203014093 @default.
• W9256820 hasConceptScore W9256820C207001950 @default.
• W9256820 hasConceptScore W9256820C2777186326 @default.
• W9256820 hasConceptScore W9256820C2777468819 @default.
• W9256820 hasConceptScore W9256820C2778041864 @default.
• W9256820 hasConceptScore W9256820C2778729363 @default.
• W9256820 hasConceptScore W9256820C2779129087 @default.
• W9256820 hasConceptScore W9256820C2779282312 @default.
• W9256820 hasConceptScore W9256820C2780007613 @default.
• W9256820 hasConceptScore W9256820C2911091166 @default.
• W9256820 hasConceptScore W9256820C515207424 @default.
• W9256820 hasConceptScore W9256820C55493867 @default.
• W9256820 hasConceptScore W9256820C71924100 @default.
• W9256820 hasConceptScore W9256820C86803240 @default.
• W9256820 hasConceptScore W9256820C98274493 @default.
• W9256820 hasLocation W92568201 @default.
• W9256820 hasOpenAccess W9256820 @default.
• W9256820 hasPrimaryLocation W92568201 @default.
• W9256820 hasRelatedWork W101699007 @default.
• W9256820 hasRelatedWork W1878984199 @default.
• W9256820 hasRelatedWork W189668032 @default.
• W9256820 hasRelatedWork W2046714569 @default.
• W9256820 hasRelatedWork W2081778277 @default.
• W9256820 hasRelatedWork W2320738941 @default.
• W9256820 hasRelatedWork W2410184824 @default.
• W9256820 hasRelatedWork W2482900659 @default.
• W9256820 hasRelatedWork W2499446124 @default.
• W9256820 hasRelatedWork W2523658139 @default.
• W9256820 hasRelatedWork W2555765037 @default.
• W9256820 hasRelatedWork W2565567265 @default.
• W9256820 hasRelatedWork W2573503723 @default.
• W9256820 hasRelatedWork W2582808171 @default.
• W9256820 hasRelatedWork W2653069754 @default.
• W9256820 hasRelatedWork W2979546414 @default.
• W9256820 hasRelatedWork W2983410752 @default.
• W9256820 hasRelatedWork W2984252751 @default.
• W9256820 hasRelatedWork W2984620763 @default.
• W9256820 hasRelatedWork W2985757764 @default.
• W9256820 isParatext "false" @default.
• W9256820 isRetracted "false" @default.
• W9256820 magId "9256820" @default.

• next